Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin-(9-39) in Congenital Hyperinsulinism
NCT00897676Phase 2Completed
- Start
- May 2009
- Primary completion
- Aug 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of exendin 9-39 in congenital hyperinsulinism (HI). Started May 2009; status: completed.
02
Drugs
exendin 9-39
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT00897676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00897676.